Helio Genomics AI Beats Ultrasound in Cancer Detection

A clinical study published in the Journal of Hepatology has demonstrated that an AI-powered blood-based surveillance test from Helio Genomics significantly outperforms conventional imaging for early cancer detection. In patients at high risk for hepatocellular carcinoma (HCC), the company's AI platform achieved a sensitivity of 47.8% for all HCC lesions. By comparison, conventional ultrasound imaging achieved a sensitivity of just 28.3%. This marked improvement highlights the potential of Helio Genomics' HelioLiver platform to transform liver cancer screening through blood-based diagnostics.

According to Dr. Bharat Tewarie, who became the CEO of Helio Genomics in July 2025, the future of clinical AI relies heavily on proving safety and efficacy in real-world settings rather than controlled test environments. This shift is reflected across the industry. Deloitte’s 2026 report on healthcare AI emphasizes that organizations are focusing on scaling and governing AI responsibly to deliver a measurable return on investment. Similarly, the 2026 State of Clinical AI Report by ARISE notes that long-term adoption depends entirely on demonstrating concrete value in actual clinical workflows.

For healthcare practitioners, these findings present both an opportunity and a challenge. While a 47.8% sensitivity rate offers a substantial diagnostic advantage over traditional ultrasound, integrating such algorithms into daily clinical practice requires overcoming significant barriers. Doctors face intense time pressures and legal accountability, making them hesitant to adopt tools that disrupt established routines or lack explainability. To build trust, developers must co-design AI systems alongside clinicians, ensuring the technology adapts to existing workflows rather than forcing physicians to alter their habits.

Ultimately, the transition from pilot programs to enterprise-level deployment hinges on transparent communication and rigorous scientific standards. When clinicians understand how an AI model reaches its conclusions, they can confidently explain the technology's role to patients. By prioritizing workflow integration and real-world clinical evidence, healthcare organizations can ensure that advanced diagnostic tools like HelioLiver are successfully adopted in the exam room to improve patient outcomes.